My NCBISign In

Display Settings:

Format

Send to:

Choose Destination
    Nervenarzt. 2011 Nov 13. [Epub ahead of print]

    [Cannabinoids for symptomatic therapy of multiple sclerosis.]

    [Article in German]
    Husseini L, Leussink VI, Warnke C, Hartung HP, Kieseier BC.

    Source

    Neurologische Klinik, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf , Deutschland.

    Abstract

    Spasticity represents a common troublesome symptom in patients with multiple sclerosis (MS). Treatment of spasticity remains difficult, which has prompted some patients to self-medicate with and perceive benefits from cannabis. Advances in the understanding of cannabinoid biology support these anecdotal observations. Various clinical reports as well as randomized, double-blind, placebo-controlled studies have now demonstrated clinical efficacy of cannabinoids for the treatment of spasticity in MS patients. Sativex is a 1:1 mix of delta-9-tetrahydocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, which recently received a label for treating MS-related spasticity in Germany. The present article reviews the current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option in MS.

    PMID:
    22080198
    [PubMed - as supplied by publisher]

    LinkOut - more resources

    Full Text Sources

      Supplemental Content

      Icon for Springer

      Save items

      loading

      Related citations in PubMed

      See reviews... See all...

      Recent activity

      Clear Turn Off Turn On

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk